Rabbit Work in Diabetic Retinopathy Research in the MICRON Literature
About the MICRON Research Literature
These research pages organize published studies using MICRON imaging systems by animal species and the disease or condition investigated.
All publication counts and figures reflect the complete indexed research collection.
Explore related studies through the MICRON Research Hubs or search the complete publication collection in the reSEARCH portal.
Understanding Diabetic Retinopathy
Diabetic retinopathy (DR) is a microvascular complication of diabetes associated with prolonged hyperglycemia. Over time, elevated blood glucose damages the retinal vasculature, leading to structural and functional changes that can impair vision.
Common features of diabetic retinopathy include:
- Loss of retinal capillary pericytes
- Formation of microaneurysms
- Breakdown of the blood-retinal barrier and increased vascular leakage
- Capillary non-perfusion and retinal ischemia
- Pathological retinal neovascularization in advanced disease
Diabetic macular edema (DME) and complications of proliferative diabetic retinopathy (PDR) are major causes of vision loss in affected patients.
In addition to vascular damage, diabetic retinopathy is associated with retinal neurodegeneration and glial dysfunction. These changes may occur before clinically detectable vascular lesions or develop alongside them. Their precise relationship to the onset and progression of diabetic retinopathy remains an active area of research.
Diabetic Retinopathy in Experimental Research
Animal models of diabetic retinopathy allow researchers to investigate the effects of hyperglycemia on retinal structure, vascular integrity, inflammation, and visual function.
Diabetes can be induced experimentally through chemical destruction of pancreatic insulin-producing beta cells or through genetic alterations affecting insulin production or metabolic regulation, including leptin signaling.
These models reproduce several features of early diabetic retinal disease, including:
- Blood-retinal barrier dysfunction and vascular leakage
- Retinal capillary cell loss
- Inflammatory and metabolic changes
- Inner retinal thinning and neurodegeneration
- Altered electroretinogram (ERG) responses, including reduced amplitudes or delayed response times
Longitudinal retinal imaging and functional testing allow these changes to be monitored in the same animal over time, supporting investigations of disease progression and treatment response.
However, important anatomical and biological differences limit direct translation to human diabetic retinopathy.
Mice, rats, and rabbits lack a macula and therefore cannot reproduce diabetic macular edema in its human anatomical location. Retinal thickening and vascular leakage can still be investigated, but measurements are obtained outside macular anatomy.
Diabetic rodents also generally do not develop spontaneous proliferative diabetic retinopathy within their lifespan. Consequently, experimentally induced preretinal neovascularization should not be interpreted as the natural progression of diabetic retinopathy without additional supporting evidence.
Rabbits present another limitation because their retinal blood vessels are largely confined to the medullary rays, leaving much of the retina avascular. This vascular arrangement limits their suitability for studying diffuse retinal capillary disease.
Rabbit in Diabetic Retinopathy Research
The rabbit eye is much larger than a rodent's, which makes it a practical model for ocular pharmacokinetics and for procedures that need working space.
It is not a small human eye: vitreous volume is roughly a third of the human figure, and vitreous composition and retinal vascular anatomy differ substantially. The rabbit's retinal vessels are confined to the medullary rays and much of the retina is avascular, so diffuse retinal capillary pathology has little substrate there.
Published MICRON Research: Diabetic Retinopathy in Rabbits
This page lists 4 papers from the MICRON literature, published 2013 to 2025, that study diabetic retinopathy in rabbits.
Of these publications:
- 4 studies used healthy animals to assess pharmacokinetics, drug delivery, or tolerability.
Scope of the literature collection: Publication counts reflect studies identified and indexed in the MICRON research corpus. This collection is not intended to represent an exhaustive review of all published diabetic retinopathy research.
Which imaging and experimental techniques are used in these studies?
| Technique | Papers |
|---|---|
| Electroretinography | 3 |
| Fundus Fluorescein Angiography | 3 |
| Laser Photocoagulation Models | 3 |
| Intravitreal Injection / Delivery | 2 |
| Optical Coherence Tomography | 2 |
Technique counts are paper-level co-occurrences and do not necessarily indicate that a technique was applied to the focal species or focal disease model.
Capabilities and Limitations of Imaging Techniques
A summary of what each imaging technique listed above can measure, the information it provides, and its limitations in research applications.
Electroretinography
Records the retina's electrical response to light, giving component-sensitive information about outer- and inner-retinal function. It measures function directly, which no structural method does. Full-field ERG sums across the whole retina, so a small lesion can leave the trace unchanged; focal and multifocal variants trade signal amplitude for spatial resolution.
Fundus Fluorescein Angiography
Fundus fluorescein angiography uses an injected fluorescent dye to visualize blood flow through the retinal and choroidal circulation. Sequential images show how vessels fill, identify areas of reduced or absent perfusion, and reveal dye leakage associated with vascular abnormalities.
This technique is particularly useful for evaluating vascular perfusion, blood-retinal barrier integrity, and abnormal vessel growth. Fluorescein angiography primarily shows dye distribution rather than the surrounding retinal tissue. It provides a two-dimensional (en face) view in which vessels at different depths may overlap. Cross-sectional and cellular structural details require other imaging methods, such as optical coherence tomography (OCT) or optical coherence tomography angiography (OCT-A). Vascular abnormalities that do not affect dye filling or produce leakage may also remain undetected.
Laser Photocoagulation Models
A laser lesion provokes a reproducible, quantifiable injury at a known time and place. Wavelength, power, duration, spot size, pulse mode, focus and lesion location together determine the injury produced, allowing laser exposure to be configured for different experimental endpoints. It is an induced injury, not the disease: it produces a lesion directly, bypassing the process that gives rise to comparable damage in patients.
Intravitreal Injection / Delivery
Injection into the vitreous places a substance directly into the vitreous at a known administered dose and chosen time, reducing but not eliminating systemic exposure. The injectate may be a therapeutic compound, cell preparation or viral vector, or an agent used to create the model, such as a toxin, vasoactive or excitotoxic compound, or infectious inoculum. The route bypasses surface-delivery barriers and provides direct access to the vitreous and posterior segment, but the concentration reached in a particular ocular tissue depends on distribution and clearance and is not fixed by the injected dose alone. It is invasive and discrete: each repeat dose or challenge requires another injection, and vehicle- or sham-injected controls can help separate effects of the injectate from effects of the procedure.
Optical Coherence Tomography
Optical coherence tomography provides high-resolution, cross-sectional images of ocular tissues in the living eye, allowing researchers to visualize structures at different depths. OCT is particularly useful for measuring tissue thickness, identifying structural abnormalities, and assessing the location and extent of tissue changes.
As a non-invasive imaging technique, OCT enables repeated measurements in the same eye over time, supporting longitudinal studies of disease progression and treatment response. Although OCT provides detailed structural information, it does not directly measure cellular activity or visual function. Tissue that appears structurally normal may still have functional abnormalities, making OCT a valuable companion to functional assessments such as electroretinography (ERG).
Which MICRON systems and add-ons appear?
| Instrument | Papers |
|---|---|
| Image-Guided Laser | 2 |
| MICRON III | 2 |
| MICRON IV | 2 |
| Image-Guided OCT | 1 |
Which strains and genetic lines are used?
| Strain | Papers | Reported as |
|---|---|---|
| New Zealand White | 2 | |
| Dutch Belted | 1 | Dutch belted |
| New Zealand | 1 |
Which other species appear alongside?
| Species | Papers |
|---|---|
| Mouse | 4 |
| Cynomolgus Macaque | 1 |
| Minipig | 1 |
| Rat | 1 |
What other conditions are recorded on the same papers?
| Disease | Papers |
|---|---|
| Age-Related Macular Degeneration (General) | 4 |
| Age-Related Macular Degeneration (Wet/Neovascular) | 4 |
| Choroidal Neovascularization | 4 |
| Retinal Neovascularization (General) | 3 |
| Diabetes Mellitus, Type 1 | 1 |
| Epiretinal Membrane | 1 |
Which MICRON configurations appear in this work?
Configurations recorded in these papers, and the techniques recorded alongside them.
| MICRON configuration | Papers | Most frequent techniques recorded alongside |
|---|---|---|
| Image-Guided Laser | 2 | Fundus Fluorescein Angiography (2), Intravitreal Injection / Delivery (2), Optical Coherence Tomography (2) |
| MICRON III | 2 | Electroretinography (2), Laser Photocoagulation Models (2), Fundus Fluorescein Angiography (1) |
| MICRON IV | 2 | Fundus Fluorescein Angiography (2), Intravitreal Injection / Delivery (2), Optical Coherence Tomography (2) |
| Image-Guided OCT | 1 | Fundus Fluorescein Angiography (1), Intravitreal Injection / Delivery (1), Optical Coherence Tomography (1) |
The papers
| Year | Title | Journal | Role of focal species | MICRON products | Links |
|---|---|---|---|---|---|
| 2025 | Pharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage. | Molecular Therapy | Healthy PK, delivery or tolerability | Image-Guided Laser, MICRON IV | DOI · reSEARCH |
| 2025 | PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases. | Nature Communications | Healthy PK, delivery or tolerability | Image-Guided Laser, Image-Guided OCT, MICRON IV | DOI · reSEARCH |
| 2020 | Sustained treatment of retinal vascular diseases with self-aggregating sunitinib microparticles. | Nature Communications | Healthy PK, delivery or tolerability | MICRON III | DOI · reSEARCH |
| 2013 | Sustained delivery of a HIF-1 antagonist for ocular neovascularization. | Journal of Controlled Release | Healthy PK, delivery or tolerability | MICRON III | DOI · reSEARCH |
Browse all hubs at MICRON Research Hubs. The full corpus is searchable in the reSEARCH portal.